Trial Profile

A global phase 2 study of cizutamig in "second" autoimmune disease indication

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cizutamig (Primary)
Indications Autoimmune disorders
Focus Therapeutic Use

Most Recent Events

30 Jan 2026 New trial record
08 Jan 2026 According to Candid Therapeutics media release, the company is advancing cizutamig into global Phase 2 studies in two autoimmune disease indications in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com